Migraines that treat headaches reduce symptoms such as dizziness

A drug called UbrogePant is now found, which is already used to treat migraines, to reduce non-quiet symptoms that often reach hours that precede the migraine itself-which makes it the first known drug that works on these early symptoms.

Before the exhausted migraine of migraines affects, many people suffer from the stage of Broadum as they get warning signs, such as sensitivity to light, sound, dizziness, and stiffness of the neck, which can cause a significant disruption of daily life on their own.

Medicines developers have so far focused on treating headaches itself, and no effective treatments have been to reduce these early symptoms.

But UbrogePant showed a promise to stop mig Peter Jadsby At King’s College London and his colleagues to consider whether she can also dispel them.

They conducted a study with 438 people between the ages of 18 and 75, and had a history of migraines. Half of the participants took the dose of 100 milligrams of UbrogePant when they felt symptoms indicating that migraines were on his way, while the other half took an imaginary drug. Then, the next time the symptoms of the basement, the participants took the opposite pill.

After taking UbrogePant, it was self -reported in its ability to focus after an hour, as well as a decrease in light of light after two hours, and pain less than fatigue and neck after 3 hours, compared to what they suffered when taking the placebo. Participants reported that the dizziness and sensitivity of the sound also decreased when they took UbrogePant.

“If they take UbrogePant, it is more likely that people have a decrease in these unspecified symptoms, even before the pain begins,” says Godsby.

The study did not achieve the effect of the drug on the aura, which is another advantage early in migraines that include sensory disorders that can affect vision, such as flashing lights and blind spots.

“Given that the common inner symptoms are often functional disruption, the ability to intervene early in the chain of migraine is clinically meaning,” he says. Parisa Ghazrani At the University of Oslo Metropolitan in Norway. She adds that more studies are needed to confirm that they are widely applicable, though.

“This research shows the possibility that migraine treatments will reduce these early symptoms, as well as prevent the main headache stage of the attack,” he says. Rob musicWhich leads the health of migraines in the United Kingdom. “We look forward to seeing more research in this field to help reduce the impact of migraines for 1 out of 7 with this situation.”

Topics: